These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 34156585)

  • 1. US Food and Drug Administration regulatory updates in neuro-oncology.
    Mehta GU; Barone AK; Bradford D; Larkins E; Kim J; Pai-Scherf L; Jaigirdar A; Shah M; Wedam S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA; Singh H
    J Neurooncol; 2021 Jul; 153(3):375-381. PubMed ID: 34156585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).
    Sharp J; Prasad V
    BMC Cancer; 2022 Jan; 22(1):70. PubMed ID: 35034621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016.
    Zhou J; Vallejo J; Kluetz P; Pazdur R; Kim T; Keegan P; Farrell A; Beaver JA; Sridhara R
    J Natl Cancer Inst; 2019 May; 111(5):449-458. PubMed ID: 30085269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
    Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
    Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing.
    Vivot A; Boutron I; Béraud-Chaulet G; Zeitoun JD; Ravaud P; Porcher R
    Sci Rep; 2017 Jul; 7(1):6882. PubMed ID: 28761069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States.
    Zaim R; Redekop K; Uyl-de Groot CA
    J Cancer Policy; 2022 Sep; 33():100346. PubMed ID: 35779788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in the approval of cancer therapies by the FDA in the twenty-first century.
    Scott EC; Baines AC; Gong Y; Moore R; Pamuk GE; Saber H; Subedee A; Thompson MD; Xiao W; Pazdur R; Rao VA; Schneider J; Beaver JA
    Nat Rev Drug Discov; 2023 Aug; 22(8):625-640. PubMed ID: 37344568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).
    Elbaz J; Haslam A; Prasad V
    Cancer Med; 2024 Apr; 13(8):e7190. PubMed ID: 38659418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer.
    Shah M; Wedam S; Cheng J; Fiero MH; Xia H; Li F; Fan J; Zhang X; Yu J; Song P; Chen W; Ricks TK; Chen XH; Goldberg KB; Gong Y; Pierce WF; Tang S; Theoret MR; Pazdur R; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2021 Mar; 27(5):1220-1226. PubMed ID: 33055172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
    Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
    BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
    Hilal T; Sonbol MB; Prasad V
    JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.
    Hirschfeld S; Ho PT; Smith M; Pazdur R
    J Clin Oncol; 2003 Mar; 21(6):1066-73. PubMed ID: 12637472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.
    Arondekar B; Duh MS; Bhak RH; DerSarkissian M; Huynh L; Wang K; Wojciehowski J; Wu M; Wornson B; Niyazov A; Demetri GD
    Clin Cancer Res; 2022 Jan; 28(1):27-35. PubMed ID: 34667027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018.
    DeMartino PC; Miljkovic MD; Prasad V
    JAMA Intern Med; 2021 Feb; 181(2):162-167. PubMed ID: 33165499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.